UNITED THERAPEUTICS Corp — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
United Therapeutics (UTC) and Liquidia Technologies settled all pending patent litigation (5 cases across multiple jurisdictions). Liquidia pays UTC $185M immediately for past infringement damages (June 2, 2025 onward) plus $145.4M in two installments (Jan 31, 2027 and Apr 30, 2027) for prospective damages from ongoing Yutrepia sales to PH-ILD patients. UTC pays Liquidia $10M to resolve one case. Liquidia must immediately remove PH-ILD indication from Yutrepia label, cease marketing for PH-ILD, and restrict future sales to PAH-only patients. All litigation dismissed with prejudice except claims against individual Robert Roscigno.
Why this rating
Settlement eliminates material litigation risk and secures ~$330M net inflow (1.5% of market cap). PH-ILD market restriction limits Liquidia's future revenue but de-risks UTC. Moderate significance given company size.
Tradability signal
NO TRADE
No trade: positive news with only -0.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.14% over 4 hrs, n=78). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $533.04 | +10 min · unknown $528.97 ▼ 0.76% | +30 min · unknown $540.51 ▲ 1.40% | +1 hr · unknown $540.55 ▲ 1.41% | +4 hrs · unknown $544.14 ▲ 2.08% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.